Norway· NO-ID_53E7FE55-1865-40F3-90F0-8902E6F23DE8
Cyramza
A ramucirumab product containing ramucirumab, registered in Norway by Eli Lilly Nederland B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ramucirumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FG02 (ramucirumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Ramucirumab · ATC L01FG02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ramucirumab costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ramucirumab · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$200.15
The record
At a glance
FEST (Norway)- Active substance
- Ramucirumab
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Norway (NO)
- ATC code
- L01FG02
- ATC class
- Ramucirumab
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_53E7FE55-1865-40F3-90F0-8902E6F23DE8
- no_varenummer18063450NOK 34753.8
- no_varenummer57524610NOK 6979.8
- gtin300020409556
- gtin300020408559
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
141 interactions on record for ramucirumab.
Graded by severity as the source publishes them — 110 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ramucirumab · interactions on record
141 records
- 110 severe
- 31 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ramucirumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCYRAMZAEli Lilly Nederland B.V., Utrecht
- FinlandCyramzaEli Lilly Nederland B.V
- BelgiumCyramza 10 mg/mlEli Lilly Nederland
- SwedenCyramza 10 mg/ml Koncentrat till infusionsvätska, lösningEli Lilly Nederland B.V.
- IrelandCyramza 10 mg/ml Concentrate for solution for infusionEli Lilly Nederland B.V.
- IcelandCyramzaEli Lilly Nederland B.V.*
- PolandCyramzaEli Lilly Nederland B.V.
- SpainCYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Cyramza
- Liechtenstein · Cyramza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8e5cd8c-0e76-4e4e-b8a4-337e72d1840c GET /v1/drugs/b8e5cd8c-0e76-4e4e-b8a4-337e72d1840c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Ramucirumab",
"merkevare_id": "ID_53E7FE55-1865-40F3-90F0-8902E6F23DE8",
"name_form_strength": "Cyramza kons til inf oppl 10 mg/ml",
"prescription_group": "C"
}See everything about ramucirumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.